Hua Medicine

Hua Medicine (Shanghai) Ltd. develops and commercializes T2D therapies in China, featuring the oral glucokinase inhibitor HuaTangNing (Dorzagliatin/HMS5552) alone and with Metformin, Sitagliptin, or Empagliflozin. It also studies mGLUR5 for PD‑LID.

Headquarters: China (CHN)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 285
HQ: Shanghai

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
2552	Hua Medicine Cap: 3.1B \| P/E: 2.6	EQUITY	HKG	HKD	KYG4644K1022	Active	📈